These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26350916)

  • 1. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Barkas F; Elisaf M; Milionis H
    Atherosclerosis; 2015 Nov; 243(1):60-4. PubMed ID: 26350916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis.
    Akioyamen LE; Tu JV; Genest J; Ko DT; Coutin AJS; Shan SD; Chu A
    Angiology; 2019 Sep; 70(8):726-736. PubMed ID: 30871330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do statins reduce the incidence of stroke in familial hypercholesterolemia?
    Vuorio AF; Kovanen PT
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):349-53. PubMed ID: 21438814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Rallidis LS; Triantafyllis AS; Tsirebolos G; Katsaras D; Rallidi M; Moutsatsou P; Lekakis J
    Atherosclerosis; 2016 Jun; 249():17-21. PubMed ID: 27062405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening.
    Kjærgaard KA; Christiansen MK; Schmidt M; Olsen MS; Jensen HK
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28652386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up.
    Skoumas I; Ioakeimidis N; Vlachopoulos C; Chrysohoou C; Michalakeas C; Georgakopoulos C; Katsi V; Panagiotakos D; Tousoulis D
    Angiology; 2018 Mar; 69(3):242-248. PubMed ID: 28681648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Lozano P; Henrikson NB; Dunn J; Morrison CC; Nguyen M; Blasi PR; Anderson ML; Whitlock EP
    JAMA; 2016 Aug; 316(6):645-55. PubMed ID: 27532919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Bos S; Duvekot MH; Ten Kate GR; Verhoeven AJ; Mulder MT; Schinkel AF; Nieman K; Watts GF; Sijbrands EJ; Roeters van Lennep JE
    Atherosclerosis; 2017 Jan; 256():62-66. PubMed ID: 28012444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia.
    Harada-Shiba M; Sugisawa T; Makino H; Abe M; Tsushima M; Yoshimasa Y; Yamashita T; Miyamoto Y; Yamamoto A; Tomoike H; Yokoyama S
    J Atheroscler Thromb; 2010 Jul; 17(7):667-74. PubMed ID: 20534948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study.
    Toleikyte I; Retterstøl K; Leren TP; Iversen PO
    Circulation; 2011 Oct; 124(15):1606-14. PubMed ID: 21911783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies.
    Knickelbine T; Lui M; Garberich R; Miedema MD; Strauss C; VanWormer JJ
    J Clin Lipidol; 2016; 10(5):1182-7. PubMed ID: 27678435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients.
    Versmissen J; Oosterveer DM; Yazdanpanah M; Mulder M; Dehghan A; Defesche JC; Kastelein JJ; Sijbrands EJ
    Eur Heart J; 2011 Feb; 32(4):469-75. PubMed ID: 20595220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
    Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality.
    Besseling J; Hovingh GK; Huijgen R; Kastelein JJP; Hutten BA
    J Am Coll Cardiol; 2016 Jul; 68(3):252-260. PubMed ID: 27417002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lipid Lowering Therapy with Statins in Patients with Heterozygous Familial Hypercholesterolemia].
    Korneva VA; Kuznetsova TY; Tihova GP
    Kardiologiia; 2019 Apr; 59(3):27-35. PubMed ID: 30990138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Casula M; Scotti L; Tragni E; Merlino L; Corrao G; Catapano AL
    Atherosclerosis; 2016 Nov; 254():172-178. PubMed ID: 27750108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood.
    Braamskamp MJ; Kusters DM; Wiegman A; Avis HJ; Wijburg FA; Kastelein JJ; van Trotsenburg AS; Hutten BA
    Atherosclerosis; 2015 Aug; 241(2):427-32. PubMed ID: 26079405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.